Document:

Warrant, dated March 25, 2008, issued to Kingsbridge Capital Limited

 Exhibit 4.5 
 WARRANT 
 THE SECURITIES EVIDENCED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS
SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION. 
 MARCH 25, 2008 
 Warrant to Purchase up to 330,000 shares of Common Stock of Corcept Therapeutics Incorporated (the “Company”). 
 In consideration for Kingsbridge Capital Limited (the “Investor”) agreeing to enter into that certain Common Stock Purchase Agreement,
dated as of the date hereof, between the Investor and the Company (the “Agreement”), the Company hereby agrees that the Investor or any other Warrant Holder (as defined below) is entitled, on the terms and conditions set forth
below, to purchase from the Company at any time during the Exercise Period (as defined below) up to 330,000 fully paid and non-assessable shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at the
Exercise Price (as defined below), as the same may be adjusted from time to time pursuant to Section 6 hereof. The resale of the shares of Common Stock or other securities issuable upon exercise or exchange of this Warrant is subject to the
provisions of the Registration Rights Agreement. Capitalized terms used herein and not otherwise defined shall have the meanings given them in the Agreement. 
 Section 1. Definitions. 
 “Affiliate” shall mean any Person that, directly or
indirectly through one or more intermediaries, controls or is controlled by, or is under direct or indirect common control with any other Person. For the purposes of this definition, “control,” when used with respect to any Person,
means the power to direct the management and policies of such Person, directly or indirectly through the ownership of voting securities, and the term “controls” and “controlled” have meanings correlative to the
foregoing. 
 “Closing Price” as of any particular day shall mean the closing price per share of the Company’s Common
Stock as reported by Bloomberg L.P. on such day. 
 “Exercise Period” shall mean that period beginning six months after the
date of this Warrant and continuing until (i) the expiration of the five-year period thereafter, or (ii) a Funding Default, subject in each case to earlier termination in accordance with Section 6 hereof. 

 “Exercise Price” as of the date hereof shall mean three dollars fifty two and a half
cents ($3.525), representing 125% of the average Closing Price of the Common Stock during the five (5) Trading Days immediately preceding the date of this Warrant. 
 “Funding Default” shall mean a failure by Investor to accept a Draw Down Notice made by the Company and to acquire and pay for the Shares in accordance therewith within three (3) Trading Days
following the delivery of such Shares to the Investor, provided such Draw Down Notice was made in accordance with the terms and conditions of the Agreement (including the satisfaction or waiver of the conditions to the obligation of the Investor to
accept a Draw Down set forth in Article VII of the Agreement), provided further, that such failure was reasonably within the control of the Investor. 
 “Per Share Warrant Value” shall mean the difference resulting from subtracting the Exercise Price from the Closing Price on the Trading Day immediately preceding the Exercise Date. 
 “Person” shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust or other entity or
organization, including a government or political subdivision or an agency or instrumentality thereof. 
 “Principal Market”
shall mean the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, the American Stock Exchange or the New York Stock Exchange, whichever is at the time the principal trading exchange or market for the Common Stock.

 “SEC” shall mean the United States Securities and Exchange Commission. 
 “Trading Day” shall mean any day other than a Saturday or a Sunday on which the Principal Market is open for trading in equity
securities. 
 “Warrant Holder” shall mean the Investor or any permitted assignee or permitted transferee of all or any
portion of this Warrant. 
 “Warrant Shares” shall mean those shares of Common Stock received upon exercise of this Warrant.

 Section 2. Exercise. 
 (a) Method of Exercise. This Warrant may be exercised in whole or in part (but not as to a fractional share of Common Stock), at any time and from time to time during the Exercise Period, by the Warrant Holder by surrender of this
Warrant, with the form of exercise attached hereto as Exhibit A completed and duly executed by the Warrant Holder (the “Exercise Notice”), to the Company at the address set forth in Section 10.4 of the Agreement,
accompanied by payment of the Exercise Price multiplied by the number of shares of Common Stock for which this Warrant is being exercised (the “Aggregate Exercise Price”). The later of the date on which an Exercise Notice or payment
of the Exercise Price (unless this Warrant is exercised in accordance with Section 2(c) below) is received by the Company in accordance with this clause (a) shall be deemed an “Exercise Date.” 

 (b) Payment of Aggregate Exercise Price. Subject to paragraph (c) below, payment of the
Aggregate Exercise Price shall be made by wire transfer of immediately available funds to an account designated by the Company. If the amount of the payment received by the Company is less than the Aggregate Exercise Price, the Warrant Holder will
be notified of the deficiency and shall make payment in that amount within three (3) Trading Days. In the event the payment exceeds the Aggregate Exercise Price, the Company will refund the excess to the Warrant Holder within five
(5) Trading Days of receipt. 
 (c) Cashless Exercise. In the event that the Warrant Shares to be received by the Warrant Holder
upon exercise of the Warrant may not be resold pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act, and applicable state laws, the Warrant Holder may, as an alternative to payment of
the Aggregate Exercise Price upon exercise in accordance with paragraph (b) above, elect to effect a cashless exercise by so indicating on the Exercise Notice and including a calculation of the number of shares of Common Stock to be issued upon
such exercise in accordance with the terms hereof (a “Cashless Exercise”). If a registration statement on Form S-1 under the Securities Act, or such other form as deemed appropriate by counsel to the Company for the registration for
the resale by the Warrant Holder of (x) the shares of Common Stock of the Company that may be purchased under the Agreement, (y) the Warrant Shares, or (z) any securities issued or issuable with respect to any of the foregoing by way
of exchange, stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise, has been declared effective by the SEC and remains effective, the Company may, in
its sole discretion, permit the Warrant Holder to effect a Cashless Exercise or require the Warrant Holder to pay the Exercise Price of the Warrant Shares being purchased by the Warrant Holder under this Warrant. In the event of a Cashless Exercise,
the Warrant Holder shall receive that number of shares of Common Stock determined by (i) multiplying the number of Warrant Shares for which this Warrant is being exercised by the Per Share Warrant Value and (ii) dividing the product by the
Closing Price on the Trading Day immediately preceding the Exercise Date, rounded to the nearest whole share. The Company shall cancel the total number of Warrant Shares equal to the excess of the number of the Warrant Shares for which this Warrant
is being exercised over the number of Warrant Shares to be received by the Warrant Holder pursuant to such Cashless Exercise. 
 (d)
Replacement Warrant. In the event that the Warrant is not exercised in full, the number of Warrant Shares shall be reduced by the number of such Warrant Shares for which this Warrant is exercised, and the Company, at its expense, shall
forthwith issue and deliver to or upon the order of the Warrant Holder a new Warrant of like tenor in the name of the Warrant Holder, reflecting such adjusted number of Warrant Shares. 
 Section 3. Ten Percent Limitation. The Warrant Holder may not exercise this Warrant such that the number of Warrant Shares to be received pursuant
to such exercise aggregated with all other shares of Common Stock that are then beneficially owned or deemed to be beneficially owned by the Warrant Holder would result in the Warrant Holder owning more than 9.9% of all of such Common Stock as would
be outstanding on such Exercise Date, as determined in accordance with Section 13(d) of the Exchange Act. 

 Section 4. Delivery of Warrant Shares. 
 (a) Subject to the terms and conditions of this Warrant, as soon as practicable after the exercise of this Warrant in full or in part, and in any event
within ten (10) Trading Days thereafter, the Company at its expense (including, without limitation, the payment by it of any applicable issue taxes) will cause to be issued in the name of and delivered to the Warrant Holder, or as the Warrant
Holder may lawfully direct, a certificate or certificates for, or make deposit with the Depositary Trust Company via book-entry of, the number of validly issued, fully paid and non-assessable Warrant Shares to which the Warrant Holder shall be
entitled on such exercise, together with any other stock or other securities or property (including cash, where applicable) to which the Warrant Holder is entitled upon such exercise in accordance with the provisions hereof. 
 (b) This Warrant may not be exercised as to fractional shares of Common Stock. In the event that the exercise of this Warrant, in full or in part, would
result in the issuance of any fractional share of Common Stock, then in such event the Warrant Holder shall receive the number of shares rounded to the nearest whole share. 
 Section 5. Representations, Warranties and Covenants of the Company. 
 (a) The Warrant Shares, when issued in accordance with the terms hereof, will be duly authorized and, when paid for or issued in accordance with the
terms hereof, shall be validly issued, fully paid and non-assessable. 
 (b) The Company shall take all commercially reasonable action and
proceedings as may be required and permitted by applicable law, rule and regulation for the legal and valid issuance of this Warrant and the Warrant Shares to the Warrant Holder. 
 (c) The Company has authorized and reserved for issuance to the Warrant Holder the requisite number of shares of Common Stock to be issued pursuant to
this Warrant. The Company shall at all times reserve and keep available, solely for issuance and delivery as Warrant Shares hereunder, such shares of Common Stock as shall from time to time be issuable as Warrant Shares. 
 (d) From the date hereof through the last date on which this Warrant is exercisable, the Company shall take all steps commercially reasonable to ensure
that the Common Stock remains listed or quoted on the Principal Market. 

 Section 6. Adjustment of the Exercise Price. The Exercise Price and, accordingly, the number of
Warrant Shares issuable upon exercise of the Warrant, shall be subject to adjustment from time to time upon the happening of certain events as follows: 
 (a) Reclassification, Consolidation, Merger, Mandatory Share Exchange, Sale or Transfer. 
 (i) Upon
occurrence of any of the events specified in subsection (a)(ii) below (the “Adjustment Events”) while this Warrant is unexpired and not exercised in full, the Warrant Holder may in its sole discretion require the Company, or any
successor or purchasing corporation, as the case may be, without payment of any additional consideration therefor, upon surrender by the Warrant Holder of the Warrant to be replaced, to execute and deliver to the Warrant Holder a new Warrant
providing that the Warrant Holder shall have the right to exercise such new Warrant (upon terms not less favorable to the Warrant Holder than those then applicable to this Warrant) and to receive upon such exercise, in lieu of each share of Common
Stock theretofore issuable upon exercise of this Warrant, the kind and amount of shares of stock, other securities, money or property receivable upon such Adjustment Event by the holder of one share of Common Stock issuable upon exercise of this
Warrant had this Warrant been exercised immediately prior to such Adjustment Event. Such new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 6.

 (ii) The Adjustment Events shall be (1) any reclassification or change of Common Stock (other than a change in par value, as a
result of a subdivision or combination of Common Stock or in connection with an Excluded Merger or Sale), (2) any consolidation, merger or mandatory share exchange of the Company with or into another corporation (other than a merger or
mandatory share exchange with another corporation in which the Company is a continuing corporation and which does not result in any reclassification or change other than a change in par value or as a result of a subdivision or combination of Common
Stock), other than (each of the following referred to as an “Excluded Merger or Sale”) a transaction involving (A) sale of all or substantially all of the assets of the Company, (B) any merger, consolidation or similar
transaction where the consideration payable to the shareholders of the Company by the acquiring Person consists substantially of cash or publicly traded securities, or a combination thereof, or where the acquiring Person does not agree to assume the
obligations of the Company under outstanding warrants (including this Warrant). In the event of an Excluded Merger or Sale, the Company shall deliver a notice to the Warrant Holder at least 10 days before the consummation of such Excluded Merger or
Sale, the Warrant Holder may exercise this Warrant at any time before the consummation of such Excluded Merger or Sale (and such exercise may be made contingent upon the consummation of such Excluded Merger or Sale), and any portion of this Warrant
that has not been exercised before consummation of such Excluded Merger or Sale shall terminate and expire, and shall no longer be outstanding. 
 (b) Subdivision or Combination of Shares. If the Company, at any time while this Warrant is unexpired and not exercised in full, shall subdivide its Common Stock, the Exercise Price shall be proportionately reduced as of the
effective date of such subdivision, or, if the Company shall take a record of holders of its Common Stock for the purpose of so subdividing its Common Stock, as of such record date, whichever is earlier. If the Company, at 

 
any time while this Warrant is unexpired and not exercised in full, shall combine its Common Stock, the Exercise Price shall be proportionately increased as
of the effective date of such combination, or, if the Company shall take a record of holders of its Common Stock for the purpose of so combining its Common Stock, as of such record date, whichever is earlier. 
 (c) Stock Dividends. If the Company, at any time while this Warrant is unexpired and not exercised in full, shall pay a dividend or other
distribution in shares of Common Stock to all holders of Common Stock, then the Exercise Price shall be adjusted, as of the date the Company shall take a record of the holders of its Common Stock for the purpose of receiving such dividend or other
distribution (or if no such record is taken, as at the date of such payment or other distribution), to that price determined by multiplying the Exercise Price in effect immediately prior to such payment or other distribution by a fraction:
(i) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be the total number of shares of Common Stock
outstanding immediately after such dividend or distribution. The provisions of this subsection (c) shall not apply under any of the circumstances for which an adjustment is provided in subsections (a) or (b). 
 (d) Liquidating Dividends, Etc. If the Company, at any time while this Warrant is unexpired and not exercised in full, makes a distribution of its
assets or evidences of indebtedness to the holders of its Common Stock as a dividend in liquidation or by way of return of capital or other than as a dividend payable out of earnings or surplus legally available for dividends under applicable law or
any distribution to such holders made in respect of the sale of all or substantially all of the Company’s assets (other than under the circumstances provided for in the foregoing subsections (a) through (c)), then the Warrant Holder shall
be entitled to receive upon exercise of this Warrant in addition to the Warrant Shares receivable in connection therewith, and without payment of any consideration other than the Exercise Price, the kind and amount of such distribution per share of
Common Stock multiplied by the number of Warrant Shares that, on the record date for such distribution, are issuable upon such exercise of the Warrant (with no further adjustment being made following any event which causes a subsequent adjustment in
the number of Warrant Shares issuable), and an appropriate provision therefor shall be made a part of any such distribution. The value of a distribution that is paid in other than cash shall be determined in good faith by the Board of Directors of
the Company. Notwithstanding the foregoing, in the event of a proposed dividend in liquidation or distribution to the shareholders made in respect of the sale of all or substantially all of the Company’s assets, the Company shall deliver a
notice to the Warrant Holder at least 10 days before the consummation of such event, the Warrant Holder may exercise this Warrant at any time before the consummation of such event (and such exercise may be made contingent upon the consummation of
such event), and any portion of this Warrant that has not been exercised before consummation of such event shall terminate and expire, and shall no longer be outstanding. 
 (e) Adjustment for Spin Off. If, for any reason, prior to the exercise of this Warrant in full, the Company spins off or otherwise divests itself of a part of its business or operations or disposes all or a
part of its assets in a transaction (a “Spin Off”) in which the Company does not receive compensation for such business, operations or assets, but causes securities of another entity (“Spin Off Securities”) to be
issued to all or substantially all holders of Common Stock, then the Company shall cause (i) to be reserved Spin Off Securities equal to 

 
the number thereof which would have been issued to the Warrant Holder in the event that the entire unexercised portion of this Warrant outstanding on the
record date (the “Record Date”) for determining the number of Spin Off Securities to be issued to holders of Common Stock had been exercised by the Warrant Holder as of the close of business on the Trading Day immediately prior to
the Record Date (the “Reserved Spin Off Shares”), and (ii) to be issued to the Warrant Holder on the exercise of all or any unexercised portion of this Warrant, such amount of the Reserved Spin Off Shares equal to (x) the
Reserved Spin Off Shares multiplied by (y) a fraction, of which (I) the numerator is the unexercised portion of this Warrant then being exercised, and (II) the denominator is the aggregate amount of the unexercised portion of this Warrant.

 Section 7. Notice of Adjustments. Whenever the Exercise Price or number of Warrant Shares shall be adjusted pursuant to
Section 6 hereof, the Company shall promptly prepare a certificate signed by its Chief Executive Officer or Chief Financial Officer setting forth in reasonable detail the event requiring the adjustment, the amount of the adjustment, the method
by which such adjustment was calculated (including a description of the basis on which the Company’s Board of Directors made any determination hereunder), and the Exercise Price and number of Warrant Shares purchasable at that Exercise Price
after giving effect to such adjustment, and shall promptly cause copies of such certificate to be sent by overnight courier to the Warrant Holder. 
 Section 8. No Impairment. The Company will not, by amendment of its Certificate of Incorporation or By-Laws or through any reorganization, transfer of assets, consolidation, merger, dissolution or issue or sale of securities, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the Warrant Holder against impairment. Without limiting the generality of the foregoing, the Company (a) will not increase the par value of any Warrant Shares above the amount payable therefor on such exercise, and
(b) will take all such action as may be reasonably necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares on the exercise of this Warrant. 
 Section 9. Rights As Stockholder. Except as set forth in Section 6 above, prior to exercise of this Warrant, the Warrant Holder shall not be
entitled to any rights as a stockholder of the Company with respect to the Warrant Shares, including (without limitation) the right to vote such shares, receive dividends or other distributions thereon or be notified of stockholder meetings.

 Section 10. Replacement of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of the Warrant and, in the case of any such loss, theft or destruction of the Warrant, upon delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such
mutilation, on surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
 Section 11. Choice of Law. This Warrant shall be construed under the laws of the State of New York. 

 Section 12. Entire Agreement; Amendments. Except for any written instrument concurrent or
subsequent to the date hereof executed by the Company and the Investor, this Warrant, the Agreement and the Registration Rights Agreement contain the entire understanding of the parties with respect to the matters covered hereby and thereby. No
provision of this Warrant may be waived or amended other than by a written instrument signed by the party against whom enforcement of any such amendment or waiver is sought. 
 Section 13. Restricted Securities. 
 (a) Registration or Exemption Required. This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, in reliance upon the provisions of Section 4(2) thereof
and Regulation D promulgated thereunder, and/or upon such other exemption from the registration requirements of the Securities Act as may be available with respect to this Warrant. This Warrant and the Warrant Shares issuable upon exercise of this
Warrant may not be resold except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws. 
 (b) Legend. Any replacement Warrants issued pursuant to Section 2 and Section 10 hereof and, unless a registration statement has been
declared effective by the SEC in accordance with the Securities Act, with respect thereto, any Warrant Shares issued upon exercise hereof, shall bear the following legend: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE
BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED,
ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION.” 
 (c) No Other Legend or Stock Transfer Restrictions. No legend other than the one specified in Section 13(b) has been or shall be placed on
the share certificates representing the Warrant Shares and no instructions or “stop transfer orders” (so called “stock transfer restrictions”) or other restrictions have been or shall be given to the Company’s
transfer agent with respect thereto other than as expressly set forth in this Section 13. 
 (d) Assignment. Assuming the
conditions of Section 13(a) above regarding registration or exemption have been satisfied, the Warrant Holder may sell, transfer, assign, pledge or otherwise dispose of this Warrant (each of the foregoing, a “Transfer”), in
whole or in part, but only to an Affiliate of the Warrant Holder. The Warrant Holder shall deliver a written notice to Company, substantially in the form of the Assignment attached hereto as Exhibit B, 

 
indicating the person or persons to whom the Warrant shall be Transferred and the respective number of warrants to be Transferred to each assignee. The
Company shall effect the Transfer within ten (10) days, and shall deliver to the Transferee(s) designated by the Warrant Holder a Warrant or Warrants of like tenor and terms for the appropriate number of shares. In connection with and as a
condition of any such proposed Transfer, the Company may request the Warrant Holder to provide an opinion of counsel to the Warrant Holder in form and substance reasonably satisfactory to the Company to the effect that the proposed Transfer complies
with all applicable federal and state securities laws. 
 (e) Investor’s Compliance. Nothing in this Section 13 shall affect
in any way the Investor’s obligations under any agreement to comply with all applicable securities laws upon resale of the Common Stock. 
 Section 14. Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be given in accordance with Section 10.4 of the Agreement. 
 Section 15. Miscellaneous. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such change, waiver, discharge or termination is sought. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The
invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 
 Section 16. Company Call Right. 
 (a) If a Funding Default occurs, the Company shall have the right to demand the surrender
of this Warrant or any remaining portion thereof, Warrant Shares and/or cash from the Investor as follows (the “Call Right”): 
 (i) If the Investor has not previously exercised this Warrant in full, then the Company shall have a right to demand the surrender of this Warrant, or remaining portion thereof, from the Investor without compensation, and the Investor shall
promptly surrender this Warrant, or remaining portion thereof. Following such demand for surrender, this Warrant shall automatically be deemed to have been canceled and shall have no further force or effect. 
 (ii) If, prior to receiving a Call Right Notice (as defined below), the Investor has previously exercised this Warrant with respect to some or all of
the Warrant Shares, and the Investor has not previously sold such Warrant Shares, then Company shall have a right to purchase from the Investor that number of shares of Common Stock equal to the number of shares of Common Stock issued in connection
with the exercise(s) of the Warrant, at a repurchase price per share equal to the price per share paid by the Investor in connection with such exercise(s). For greater certainty, (a) if Warrant Shares were exercised for cash, the purchase price
per share under the Call Right shall be equal to the Exercise Price, (b) if Warrant Shares were exercised on a cashless exercise basis, the purchase price per share for such Warrant Shares under the Call Right shall be zero, and (c) if
such Warrant Shares were exercised on both 

 
a cash and cashless exercise basis, the purchase price per share under the Call Right shall be equal to the total amount of cash paid in connection with such
cash exercise(s) divided by the total number of shares of Common Stock issued in connection with all exercises of the Warrant (whether on a cash or cashless basis). 
 (iii) If, prior to receiving a Call Right Notice, the Investor has previously exercised this Warrant with respect to some or all of the Warrant Shares, and the Investor subsequently sold such Warrant Shares, then the
Investor shall remit to the Company the excess, if any, of (x) the proceeds received by Investor through the sale of such Warrant Shares, over (y) the aggregate Exercise Price for such Warrant Shares. In the event that the Investor
obtained such Warrant Shares through a Cashless Exercise, then the Investor shall instead remit to the Company all proceeds received by the Investor through the sale of such Warrant Shares. For the avoidance of doubt, in the event that the Investor
has sold some or all of the Warrant Shares prior to receiving a Call Right Notice, then the right set forth in this paragraph (iii) shall constitute the sole Call Right of the Company with respect to such Warrant Shares which have been sold.

 (b) Company may exercise the Call Right by delivering a notice (the “Call Right Notice”) to Investor within thirty
(30) days after the occurrence of a Funding Default. On the tenth (10th) business day following delivery of the Call Right Notice to Investor, Company shall tender the purchase price, if any, and Investor shall tender shares of Common
Stock, if any, to be sold to Company pursuant to the Call Right Notice, immediately following which Company and Investor shall consummate such purchase and sale. The Call Right shall survive both the assignment of the Warrant by the Investor and the
disposition of the Warrant Shares by the Investor following exercise of the Warrant. 
 [Remainder of Page Intentionally Left Blank.
Signature Page Follows.] 

 IN WITNESS WHEREOF, this Warrant was duly executed by the undersigned, thereunto duly authorized, as of
the date first set forth above. 
  

			
	CORCEPT THERAPEUTICS INCORPORATED
		
	 By:
	 	 /s/ Joseph K. Belanoff, M.D.

		 	Name: Joseph K. Belanoff, M.D.
		 	Title: Chief Executive Officer

 Investor acknowledges and agrees to the terms and conditions of this Warrant. 
  

			
	KINGSBRIDGE CAPITAL LIMITED
		
	 By:
	 	 /s/Adam Gurney

		 	Adam Gurney
		 	Managing Director

 EXHIBIT A TO THE WARRANT 
 EXERCISE FORM 
 CORCEPT THERAPEUTICS INCORPORATED 
 The undersigned hereby irrevocably exercises the right to purchase
                     shares of Common Stock of Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), evidenced
by the attached Warrant, and (CIRCLE EITHER (i) or (ii)) (i) tenders herewith payment of the Aggregate Exercise Price with respect to such shares in full, in the amount of
$            , in cash, by certified or official bank check or by wire transfer for the account of the Company or (ii) elects, pursuant to Section 2(c) of the Warrant, to convert
such Warrant into shares of Common Stock of the Company on a cashless exercise basis, all in accordance with the conditions and provisions of said Warrant. 
 The undersigned requests that stock certificates for such Warrant Shares be issued, and a Warrant representing any unexercised portion hereof be issued, pursuant to this Warrant, in the name of the registered Warrant
Holder and delivered to the undersigned at the address set forth below. 
  

			
	Dated:	 	 

  
  
  

	
	 Signature of Registered Holder
  

	 Name of Registered Holder (Print)
  

	 Address

 EXHIBIT B TO THE WARRANT 
 ASSIGNMENT 
 (To be executed by the registered Warrant Holder desiring to
transfer the Warrant) 
 FOR VALUED RECEIVED, the undersigned Warrant Holder of the attached Warrant hereby sells, assigns and transfers unto
the persons below named the right to purchase                     shares of Common Stock of Corcept Therapeutics Incorporated (the
“Company”) evidenced by the attached Warrant and does hereby irrevocably constitute and appoint                     attorney to
transfer the said Warrant on the books of the Company, with full power of substitution in the premises. 
  

			
	Dated:	 	 

  
  
  

	
	Signature
	
	 Fill in for new Registration of Warrant:
  
  

	 Name
  

	 Address
  

	 Please print name and address of assignee (including zip code number)Securities Purchase Agreement

 Exhibit 10.24 
 CORCEPT THERAPEUTICS INCORPORATED 
 SECURITIES PURCHASE AGREEMENT 
 This Securities Purchase Agreement (“Agreement”) is made as of March 14, 2008 (the “Effective Date”), by and among
Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto
(the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser”. 
 AGREEMENT 
 In consideration of the
mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and each Purchaser (severally and not jointly) hereby agree as follows: 
 SECTION 1. AUTHORIZATION OF SALE OF SECURITIES. 
 The
Company has authorized the sale and issuance of 8,923,210 shares of its Common Stock, par value $0.001 per share (the “Common Stock”) and warrants in the form of Exhibit B hereto (the “Warrants”) to purchase
an aggregate of 4,461,599 shares of Common Stock (each a “Warrant” and collectively the “Warrants”), on the terms and subject to the conditions set forth in this Agreement. The shares of Common Stock sold hereunder
at the Closing (as defined below) shall be referred to as the “Shares.” The Shares and the Warrants are referred to collectively as the “Securities”. 
 SECTION 2. AGREEMENT TO SELL AND PURCHASE THE SECURITIES. 
 2.1 Sale of Securities. At the
Closing (as defined in Section 3), the Company will sell to each Purchaser, and each Purchaser will purchase from the Company, (a) the number of Shares set forth opposite such Purchaser’s name on the Schedule of Purchasers at a
purchase price of $2.77 per Share and (b) a Warrant to purchase the number of shares of Common Stock set forth opposite such Purchaser’s name on the Schedule of Purchasers (such shares of Common Stock, the “Underlying
Shares”), which Warrant shall have an exercise price equal to $2.77 per Underlying Share, and which Warrant shall have a purchase price equal to $0.125 per Underlying Share. 
 2.2 Separate Agreement. Each Purchaser shall severally, and not jointly, be liable for only the purchase of the Securities that appear on the
Schedule of Purchasers that relate to such Purchaser. The Company’s agreement with each of the Purchasers is a separate agreement, and the sale of Securities to each of the Purchasers is a separate sale. The obligations of each Purchaser
hereunder are expressly not conditioned on the purchase by any or all of the other Purchasers of the Securities such other Purchasers have agreed to purchase. 

 SECTION 3. CLOSING AND DELIVERY. 
 3.1 Closing. The closing of the purchase and sale of the Securities (which Securities are set forth in the Schedule of Purchasers) pursuant to this Agreement (the “Closing”) shall be held on
March 28, 2008 at the offices of Latham & Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, or on such other date and place as may be agreed to by the Company and the Purchasers. At or prior to the Closing, each Purchaser
shall execute any related agreements or other documents required to be executed hereunder, dated as of the date of the Closing (the “Closing Date”). 
 3.2 Issuance of the Securities at the Closing. At the Closing, the Company shall issue to each Purchaser (a) stock certificates registered in the name of such Purchaser, or in such nominee name(s) as
designated by such Purchaser, representing the number of Shares to be purchased by such Purchaser at such Closing as set forth in the Schedule of Purchasers against payment of the purchase price for such Shares and (b) a Warrant registered in
the name of such Purchaser, or in such nominee name(s) as designated by such Purchaser, representing the number of Underlying Shares as set forth in the Schedule of Purchasers. The name(s) in which the stock certificates and Warrant are to be issued
to each Purchaser are set forth in the Investor Questionnaire and the Selling Stockholder Notice and Questionnaire in the form attached hereto as Appendix I and II (the “Investor Questionnaire” and the “Selling Stockholder
Questionnaire”, respectively), as completed by each Purchaser, which shall be provided to the Company no later than the Closing Date. The stock certificates and Warrants shall be delivered to each Purchaser promptly following the Closing
Date, but in any event within 10 business days following the Closing Date. 
 3.3 Delivery of the Registration Rights Agreement. At
the Closing, the Company and each Purchaser shall execute and deliver the Registration Rights Agreement in the form attached hereto as Appendix III (the “Registration Rights Agreement”), with respect to the registration of the
Shares and the Underlying Shares under the Securities Act of 1933, as amended (the “Securities Act”). 
 SECTION 4. REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY. 
 Except as set forth on the Schedule of Exceptions delivered to the Purchasers concurrently
with the execution of this Agreement (the “Schedule of Exceptions”), the Company hereby represents and warrants as of the date hereof to, and covenants with, the Purchasers as follows: 
 4.1 Organization and Standing. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of
Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in all jurisdictions in which the character of the
property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a material adverse effect on the business, properties, financial condition or results
or operations of the Company (a “Company Material Adverse Effect”). The Company has no subsidiaries or equity interest in any other entity. 
  

 2 

 4.2 Corporate Power; Authorization. The Company has all requisite corporate power, and has taken
all requisite corporate action, to execute and deliver this Agreement, the Warrant, the Registration Rights Agreement and the Management Rights Agreement (as defined below and collectively, the “Transaction Documents”), sell and
issue the Securities and carry out and perform all of its obligations under the Transaction Documents. Each Transaction Document constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally, including any
specific performance and (iii) with respect to the Registration Rights Agreement, as rights to indemnity or contribution may be limited by state or federal laws or public policy underlying such laws. The execution and delivery of the
Transaction Documents do not, and the performance of the Transaction Documents and the compliance with the provisions of the Transaction Documents and the issuance, sale and delivery of the Securities and the Underlying Shares by the Company will
not conflict with, or result in a breach or violation of the terms, conditions or provisions of, or constitute a default under, or result in the creation or imposition of any lien pursuant to the terms of, the Certificate of Incorporation or Bylaws
of the Company or any statute, law, rule (including federal and state securities laws and the rules and regulations of the NASDAQ Capital Market (the “Principal Market”)) applicable to the Company or regulation or any state or
federal order, judgment or decree applicable to the Company or any indenture, mortgage, lease or other material agreement or instrument to which the Company is a party or any of its properties is subject. 
 4.3 Issuance and Delivery of the Securities. The Securities have been duly authorized and, when issued and paid for in compliance with the
provisions of this Agreement, will be validly issued, fully paid and nonassessable. The Underlying Shares have been duly authorized and, upon exercise of the Warrants in accordance with their terms, including payment of the exercise price therefore,
will be validly issued, fully paid and nonassessable. The issuance and delivery of the Securities is not subject to preemptive, co-sale, right of first refusal or any other similar rights of the stockholders of the Company or any liens or
encumbrances. Assuming the accuracy of the representations made by each Purchaser in Section 5, the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act. 
 4.4 SEC Documents; Financial Statements. The Company has filed in a timely manner all documents that the Company was required to file with the
Securities and Exchange Commission (the “Commission”) under Sections 13, 14(a) and 15(d) the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since becoming subject to the requirements of the
Exchange Act. As of their respective filing dates (or, if amended prior to the date of this Agreement, when amended), all documents filed by the Company with the Commission (the “SEC Documents”) complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder. None of the SEC Documents as of their respective dates contained any untrue statement of material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Documents (the
“Financial Statements”) comply 

  

 3 

 
as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect
thereto. The Financial Statements have been prepared in accordance with United States generally accepted accounting principles consistently applied and fairly present the financial position of the Company at the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal, recurring adjustments). 
 4.5
Capitalization. All of the Company’s outstanding shares of capital stock have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and
were not issued in violation of or subject to any preemptive right or other rights to subscribe for or purchase securities. The authorized capital stock of the Company consists of 140,000,000 shares of common stock and 10,000,000 shares of
undesignated Preferred Stock. As of the Effective Date, there are no shares of Preferred Stock issued and outstanding and there are 39,549,954 shares of Common Stock issued and outstanding, of which no shares are owned by the Company. There are no
other shares of any other class or series of capital stock of the Company issued or outstanding. The Company has no capital stock reserved for issuance, except that, as of the Effective Date, there are 3,975,936 shares of Common Stock reserved for
issuance pursuant to options outstanding on such date pursuant to the Company’s 2000 Stock Option Plan and 2004 Equity Incentive Plan. There are 1,591,636 shares of Common Stock available for future issuance under the Company’s 2004 Equity
Incentive Plan and no shares of Common Stock available for future issuance under the Company’s 2000 Stock Option Plan. There are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities
having such rights) (“Voting Debt”) of the Company issued and outstanding. Except as stated above, there are no existing options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments of any
character, relating to the issued or unissued capital stock of the Company, obligating the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased
or otherwise acquired any capital stock or Voting Debt of, or other equity interest in, the Company or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant, extend or enter
into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment. The issuance of Common Stock or other securities pursuant to any provision of this Agreement or the Warrant will not give rise to any
preemptive rights or rights of first refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar rights. Except as disclosed in the SEC Documents, there are no agreements or arrangements under which the Company
or any of its Subsidiaries is obligated to register the sale of any of their securities under the Securities Act. There are no securities or instruments containing anti-dilution provisions that will be triggered by the issuance of the Securities or
the Underlying Shares. The Company has made available upon request of the Purchasers, a true, correct and complete copy of the Company’s Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate of
Incorporation”), and the Company’s Bylaws, as amended and as in effect on the date hereof (the “Bylaws”). 
 4.6 Litigation. There are no legal or governmental actions, suits or other proceedings pending or, to the Company’s knowledge, threatened against the Company before or by any court, regulatory body or administrative agency or
any other governmental agency or body, domestic, or foreign, which actions, suits or proceedings, individually or in the aggregate, could 

  

 4 

 
reasonably be expected to have a Company Material Adverse Effect. The Company is not a party to or subject to the provisions of any injunction, judgment,
decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have a Company Material Adverse Effect. 
 4.7 Governmental Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state, or local governmental authority on the
part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement or the Registration Rights Agreement except for (a) the filing of a Form D with the Commission under the Securities Act and
compliance with the securities and blue sky laws in the states and other jurisdictions in which shares of Common Stock are offered and/or sold, which compliance will be effected in accordance with such laws, (b) the approval by the Principal
Market of the listing of the Shares and the Underlying Shares and (c) the filing of one or more registration statements and all amendments thereto with the Commission as contemplated by the Registration Rights Agreement. 
 4.8 No Default or Consents. Neither the execution, delivery or performance of the Transaction Documents by the Company nor the consummation of any
of the transactions contemplated thereby (including, without limitation, the issuance and sale by the Company of the Securities and the Underlying Shares) will give rise to a right to terminate or accelerate the due date of any payment due under, or
conflict with or result in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under, or require any consent or waiver under, or result in the execution
or imposition of any lien, charge or encumbrance upon any properties or assets of the Company pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement or instrument to which the Company is a party or by which the Company
or any of its properties or businesses is bound, or any franchise, license, permit, judgment, decree, order, statute, rule or regulation applicable to the Company or violate any provision of the Certificate of Incorporation or the Bylaws, except in
each case as would not cause, either individually or in the aggregate, a Company Material Adverse Effect, and except for such consents or waivers which have already been obtained and are in full force and effect. 
 4.9 No Material Adverse Change. Since December 31, 2006, except as disclosed in the SEC Documents, there have not been any changes in the
assets, liabilities, financial condition or operations of the Company from that reflected in the Financial Statements for the year ended December 31, 2006, except changes which have not had, either individually or in the aggregate, a Company
Material Adverse Effect. 
 4.10 No General Solicitation. Neither the Company, nor any of its affiliates, nor any Person acting on its
or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act in connection with the offer or sale of the Securities. 
 4.11 No Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of any of the Securities under the Securities Act or cause this offering of the 

  

 5 

 
Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder approval provisions,
including, without limitation, under the rules and regulations of the Principal Market. 
 4.12 Board of Directors. The Company shall
take all necessary acts to have one designee (the “Longitude Capital Board Member”) of Longitude Venture Partners, L.P. (“Longitude Capital”) nominated for election to the Company’s Board of Directors, in all cases subject
to compliance with relevant Nasdaq rules and regulations and subject to the approval of such nominees by the Nominating and Corporate Governance Committee of the Board of Directors. If the Nominating and Corporate Governance Committee of the Board
of Directors does not approve any proposed Longitude Capital Board Member, Longitude Capital shall be entitled to propose another candidate who shall be reasonably acceptable to the Company and the Nominating and Corporate Governance Committee of
the Board of Directors. The Company hereby agrees that Patrick G. Enright will be elected to the Board as the Longitude Capital Board Member coincident with the Closing. The Company shall use its best efforts, including preparation of proxy
materials and solicitation of the Company’s stockholders, to have the Longitude Capital Board Member elected whenever its board seat comes up for election or for reelection. The Company’s obligations under this Section 4.12 with
respect to the Longitude Capital Board Member shall terminate in their entirety if at any time Longitude Capital beneficially owns less than 5% of the Company’s issued and outstanding Common Stock (including shares of Common Stock issuable upon
exercise of Warrants), and in such case, the Longitude Capital Board Member shall resign from the Board effective immediately. 
 4.13
Sarbanes-Oxley Act. To the knowledge of the executive officers of the Company, the Company is in material compliance with the requirements of the Sarbanes-Oxley Act of 2002 that are effective and applicable to the Company as of the date
hereof, and the rules and regulations promulgated by the Commission thereunder that are effective and applicable to the Company as of the date hereof. 
 4.14 Patents and Trademarks. To the knowledge of the executive officers of the Company, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, copyrights, licenses and other similar rights that are necessary or material for use in connection with their respective businesses as described in the SEC Documents and which the failure to so have could,
individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Except as set forth in the SEC Documents, neither the Company nor any
Subsidiary has received a written notice that the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights of any Person. Except as set forth in the SEC Documents, to the knowledge of the
executive officers of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. 
 4.15 Listing and Maintenance Requirements. Except as specified in the SEC Documents and the Schedule of Exceptions, the Company has not, in the
two years preceding the date hereof, received notice from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance requirements thereof. Except as disclosed in the SEC Documents and the Schedule
of Exceptions, the Company is in compliance with the listing and 

  

 6 

 
maintenance requirements for continued listing of the Common Stock. The issuance and sale of the Securities under this Agreement does not contravene the
rules and regulations of the Principal Market and no approval of the stockholders of the Company thereunder is required for the Company to issue and deliver to the Purchasers the Securities. 
 4.16 Disclosure. The Company understands and confirms that the Purchasers will rely on the foregoing representations and covenants in effecting
transactions in securities of the Company. To the knowledge of the executive officers of the Company, all due diligence materials regarding the Company, its business and the transactions contemplated hereby, furnished by or on behalf of the
Company to the Purchasers upon their request are, when taken together with the SEC Documents, true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading. 
 4.17 Contracts.
(a) Each indenture, contract, lease, mortgage, deed of trust, note agreement, loan or other agreement or instrument of a character that is required to be described or summarized in the SEC Reports or to be filed as an exhibit to the SEC Reports
under the Securities Act and the rules and regulations promulgated thereunder (collectively, the “Material Contracts”) is so described, summarized or filed. 
 (b) The Material Contracts to which the Company is a party have been duly and validly authorized, executed and delivered by the Company and constitute the legal, valid and binding agreements of the Company,
enforceable by and against the Company in accordance with their respective terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws relating to enforcement of creditors’
rights generally, and general equitable principles relating to the availability of remedies, except as rights to indemnity or contribution may be limited by federal or state securities laws. 
 4.18 Properties and Assets. The Company has good and marketable title to all the properties and assets described as owned by it in the
Company’s consolidated financial statements, free and clear of all liens, mortgages, pledges or encumbrances of any kind except (i) those, if any, reflected in such consolidated financial statements or (ii) those that are not material
in amount and do not adversely affect the use made and proposed to be made of such property by the Company. The Company holds its leased properties under valid and binding leases. The Company owns or leases all such properties as are necessary to
its operations as now conducted. 
 4.19 Compliance. The Company has not been advised, nor does it have any reason to believe, that it
is not conducting its business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, including, without limitation, all applicable local, state and federal environmental laws and
regulations, except where failure to be so in compliance would not have a Company Material Adverse Effect. 
 4.20 Taxes. The Company
has filed on a timely basis (giving effect to extensions) all required federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and the Company does not have any knowledge of a tax
deficiency 

  

 7 

 
that has been or might be asserted or threatened against it that could have a Company Material Adverse Effect. All tax liabilities accrued through the date
hereof have been adequately provided for on the books of the Company. 
 4.21 Transfer Taxes. On the Closing Date, all stock transfer
or other taxes (other than income taxes) that are required to be paid in connection with the sale and transfer of the Securities to be sold to the Purchaser hereunder will have been fully paid or provided for by the Company and all laws imposing
such taxes will have been fully complied with. 
 4.22 Investment Company. The Company is not an “investment company” or an
“affiliated person” of, or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission
promulgated thereunder. 
 4.23 Insurance. The Company maintains insurance underwritten by insurers of recognized financial
responsibility, of the types and in the amounts that the Company reasonably believes is adequate for businesses, including, but not limited to, Directors’ and Officers’ liability insurance and insurance covering all real and personal
property owned or leased by the Company against theft, damage, destruction, acts of vandalism and all other risks customarily insured against, with such deductibles as are customary for companies in the same or similar business, all of which
insurance is in full force and effect. 
 4.24 Price of Common Stock. The Company has not taken, and will not take, directly or
indirectly, any action designed to cause or result in, or that has constituted or that might reasonably be expected to constitute, the stabilization or manipulation of the price of the shares of the Common Stock to facilitate the sale or resale of
the Shares or the Underlying Shares. 
 4.25 Governmental Permits, Etc. The Company has all franchises, licenses, certificates and
other authorizations from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company as currently conducted, except where the failure to posses
currently such franchises, licenses, certificates and other authorizations is not reasonably expected to have a Company Material Adverse Effect. 
 4.26 Internal Control over Financial Reporting; Sarbanes-Oxley Matters. The Company maintains internal control over financial reporting (as such term is defined in paragraph (f) of Rule 13a-15 under the Exchange Act) as required
by Rule 13a-15 under the Exchange Act. The Company is in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated thereunder. To the best of the
Company’s knowledge, since the end of the Company’s most recent audited fiscal year, there has been no material weakness in the design or operation of the Company’s internal control over financial reporting (whether or not remediated)
which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information. 
 4.27 Foreign Corrupt Practices. The Company, nor, to the knowledge of the Company, any director, officer, agent, employee or other Person acting on behalf of the Company 

  

 8 

 
has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 
 4.28 Employee Relations. The Company believes that its relations with its employees are good. No executive officer of the Company (as defined in
Rule 501(f) promulgated under the Securities Act) has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company is, or is
now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other agreement or any restrictive covenant involving or otherwise
affecting such executive officer’s relationship with the Company, and the continued employment of each such executive officer does not subject the Company to any liability with respect to any of the foregoing matters. 
 4.29 ERISA. The Company is in compliance in all material respects with all presently applicable provisions of the Employee Retirement Income
Security Act of 1974, as amended, including the regulations and published interpretations thereunder (herein called “ERISA”); no “reportable event” (as defined in ERISA) has occurred with respect to any “pension
plan” (as defined in ERISA) for which the Company would have any liability; the Company has not incurred and does not expect to incur liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any
“pension plan”; or (ii) Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the “Code”); and each “Pension Plan” for
which the Company would have liability that is intended to be qualified under Section 401(a) of the Code is so qualified in all material respects and nothing has occurred, whether by action or by failure to act, which would cause the loss
of such qualification. 
 SECTION 5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS. 
 5.1 Each Purchaser, severally and not jointly, represents and warrants to and covenants with the Company that: 
 (a) Purchaser, taking into account the personnel and resources it can practically bring to bear on the purchase of the Securities contemplated hereby, is
knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities presenting an investment decision like that involved in the purchase of the Securities, including investments in
securities issued by the Company, and has requested, received, reviewed and considered all information Purchaser deems relevant (including the SEC Documents) in making an informed decision to purchase the Securities. 
  

 9 

 (b) Purchaser is acquiring the Securities pursuant to this Agreement in the ordinary course of its
business and for its own account for investment only and with no present intention of distributing any of such Securities or any arrangement or understanding with any other persons regarding the distribution of such Securities, except in compliance
with Section 5.1(c). 
 (c) Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or
solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the securities purchased hereunder except in compliance with the Securities Act, applicable blue sky laws, and the rules and regulations promulgated thereunder.

 (d) Purchaser has, in connection with its decision to purchase the Securities, relied with respect to the Company and its affairs solely
upon the SEC Documents and the representations and warranties of the Company contained herein. 
 (e) Purchaser is an “accredited
investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act or a Qualified Institutional Buyer within the meaning of Rule 144A promulgated under the Securities Act. 
 (f) Purchaser has full right, power, authority and capacity to enter into this Agreement and the Registration Rights Agreement and to consummate the
transactions contemplated by this Agreement and the Registration Rights Agreement and has taken all necessary action to authorize the execution, delivery and performance of this Agreement and the Registration Rights Agreement. Upon the execution and
delivery of this Agreement and the Registration Rights Agreement by Purchaser, this Agreement and the Registration Rights Agreement shall each constitute a valid and binding obligation of Purchaser, enforceable in accordance with its terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally, including any
specific performance and (iii) with respect to the Registration Rights Agreement, as rights to indemnity or contribution may be limited by state or federal laws or public policy underlying such laws. 
 (g) Purchaser is not a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934 (a “registered
broker-dealer”) and is not affiliated with a registered broker dealer. Purchaser is not party to any agreement for distribution of any of the Securities. 
 (h) The Purchaser shall have completed or caused to be completed and delivered to the Company at no later than the Closing Date, the Investor Questionnaire and the Selling Stockholder Questionnaire for use in
preparation of the Registration Statement, and the answers to the Investor Questionnaire and the Selling Stockholder Questionnaire are true and correct in all material respects as of the date of this Agreement and will be true and correct as of the
Closing Date and the effective date of the Registration Statement; provided that the Purchasers shall be entitled to update such information by providing notice thereof to the Company before the effective date of such Registration Statement.

  

 10 

 5.2 Purchaser represents, warrants and covenants to the Company that Purchaser has not, either directly
or indirectly through an affiliate, agent or representative of the Company, engaged in any transaction in the Securities of the Company subsequent to September 30, 2007, except as set forth in filings made with the Commission pursuant to
Section 16 of the Exchange Act. Purchaser represents and warrants to and covenants with the Company that Purchaser has not engaged and will not engage in any short sales of the Company’s Common Stock prior to the effectiveness of the
Registration Statement (either directly or indirectly through an affiliate, agent or representative). 
 5.3 Purchaser understands that
nothing in this Agreement or any other materials presented to Purchaser in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. Purchaser has consulted such legal, tax and investment advisors as it, in
its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. 
 5.4 Legends. It is
understood that the Shares and the Underlying Shares may bear one or more legends in substantially the following form and substance: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR
OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES
LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES
ACT AND SUCH OTHER APPLICABLE LAWS.” 
 It is understood that the Warrants may bear one or more legends in substantially
the following form and substance: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER 

  

 11 

 
THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED
OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND IN THE
CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER
APPLICABLE LAWS.” 
 In addition stock certificates representing the Securities or the Underlying Shares may contain:

 (a) Any legend required by the laws of the State of California, including any legend required by the California Department of Corporations.

 (b) Any legend required by the blue sky laws of any other state to the extent such laws are applicable to the sale of such Securities or
Underlying Shares hereunder. 
 (c) A legend regarding affiliate status, if applicable. 
 5.5 Restricted Securities. Purchaser understands that the Securities are characterized as “restricted securities” under the federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such Securities may be resold without registration under the Securities Act
only in certain limited circumstances. In this connection, such Purchaser represents that it is familiar with Commission Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act. 

SECTION 6. CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING. 
 The Company’s obligation to complete the sale and issuance of the Securities and deliver Securities to each Purchaser, individually, as set forth in the Schedule of Purchasers at the Closing shall be subject to
the following conditions to the extent not waived by the Company: 
 6.1 Receipt of Payment. The Company shall have received payment,
by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Securities being purchased by such Purchaser at the Closing as set forth in the Schedule of Purchasers; provided, that the Company may
accept a secured promissory note from Paperboy Ventures LLC in lieu of wire transfers. 
 6.2 Representations and Warranties. The
representations and warranties made by such Purchaser in Section 5 hereof shall be true and correct in all material respects as of, and as if made on, the date of this Agreement and as of the Closing Date. 
  

 12 

 6.3 Receipt of Executed Documents. Such Purchaser shall have executed and delivered to the Company
the Registration Rights Agreement, the Investor Questionnaire and the Selling Stockholder Questionnaire. 
 6.4 Nasdaq Approval. The
Shares and the Underlying Shares shall have been approved for listing on the Nasdaq Capital Market, subject to official notice of issuance. 
 SECTION 7.
CONDITIONS TO PURCHASERS’ OBLIGATIONS AT THE CLOSING. 
 Each Purchaser’s obligation to accept delivery of the Securities and to
pay for the Securities shall be subject to the following conditions to the extent not waived by such Purchaser: 
 7.1 Representations and
Warranties Correct. The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects as of, and as if made on, the date of this Agreement and as of the Closing Date. 

7.2 Receipt of Executed Registration Rights Agreement. The Company shall have executed and delivered to the Purchasers the Registration Rights
Agreement. 
 7.3 Legal Opinion. The Purchasers shall have received an opinion of Latham & Watkins LLP, special counsel to
the Company, substantially in the form set forth in Appendix IV hereto. 
 7.4 Certificate. Each Purchaser shall have received a
certificate signed by the Chief Executive Officer and the Chief Financial or Accounting Officer to the effect that the representations and warranties of the Company in Section 4 hereof are true and correct in all material respects as of, and as
if made on, the date of this Agreement and as of the Closing Date and that the Company has satisfied in all material respects all of the conditions set forth in this Section 7. 
 7.5 Good Standing. The Company is validly existing as a corporation in good standing under the laws of Delaware. 
 7.6 Management Rights Agreement. The Company shall have executed and delivered to the Purchasers the Management Rights Agreement in a form
satisfactory to Longitude Capital. 
 7.7 Nasdaq Approval. The Shares and the Underlying Shares shall have been approved for listing
on the Nasdaq Capital Market, subject to official notice of issuance. 
 SECTION 8. BROKER’S FEE. 
 The Company and each Purchaser (severally and not jointly) hereby represent that there are no brokers or finders entitled to compensation in connection
with the sale of the Securities, and shall indemnify each other for any such fees for which they are responsible. 
  

 13 

 SECTION 9. INDEMNIFICATION. 
 9.1 Indemnification by the Company. The Company agrees to indemnify and hold harmless each of the Purchasers and each Person, if any, who controls any Purchaser within the meaning of the Securities Act (each,
an “Indemnified Party”), against any losses, claims, damages, liabilities or expenses, joint or several, to which such Indemnified Party may become subject under the Securities Act, the Exchange Act, or any other federal or state statutory
law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses (or actions in
respect thereof as contemplated below) arise out of or are based in whole or in part on any inaccuracy in the representations and warranties of the Company contained in this Agreement or any failure of the Company to perform its obligations
hereunder, and will reimburse each Indemnified Party for any legal and other expenses reasonably incurred as such expenses are reasonably incurred by such Indemnified Party in connection with investigating, defending, settling, compromising or
paying any such loss, claim, damage, liability, expense or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon
(i) the failure of such Indemnified Party to comply with the covenants and agreements contained in Section 6 above respecting sale of the Securities (including the Warrant Shares), or (ii) the inaccuracy of any representations made by
such Indemnified Party herein. 
 9.2 Indemnification by Investors. Each Purchaser shall severally, and not jointly, indemnify and
hold harmless the other Purchasers and the Company, each of its directors, and each Person, if any, who controls the Company within the meaning of the Securities Act, against any losses, claims, damages, liabilities or expenses to which the Company,
each of its directors or each of its controlling Persons may become subject, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any
litigation, if such settlement is effected with the written consent of such Purchaser) insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon (i) any
failure by such Purchaser to comply with the covenants and agreements contained in Section 6.3 above respecting the sale of the Securities (including the Warrant Shares) unless such failure by such Purchaser is directly caused by the
Company’s failure to provide written notice of a Suspension to such Purchaser or (ii) the inaccuracy of any representation made by such Purchaser herein, in each case to the extent, and will reimburse the Company, each of its directors,
and each of its controlling Persons for any legal and other expense reasonably incurred, as such expenses are reasonably incurred by the Company, each of its directors, and each of its controlling Persons in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage, liability, expense or action. No Purchaser shall be liable for the indemnification obligations of any other Purchaser. 
 SECTION 10. DIRECTORS’ AND OFFICERS’ LIABILITY INSURANCE. 
 As long as a Longitude Capital
Board Member is a member of the Board of Directors of the Company, the Company shall use its reasonable best efforts to obtain and keep Directors’ and Officers’ liability insurance in an amount reasonably acceptable to Longitude Capital to
the extent such coverage is available on terms that are commercially acceptable to the Company’s Board of Directors and consistent with industry practice. 
  

 14 

 SECTION 11. ACCESS TO INFORMATION. 
 From the date hereof until the Closing, the Company will make reasonably available to the Purchasers’ representatives, consultants and their respective counsels for inspection, such information and documents as
the Purchasers reasonably request, and will make available at reasonable times and to a reasonable extent officers and employees of the Company to discuss the business and affairs of the Company. 
 SECTION 12. USE OF PURCHASERS’ NAMES. 
 Except as
otherwise required by applicable law or regulation, the Company shall not use the Purchasers’ names or the name of any of their affiliates in any advertisement, announcement, press release or other similar public communication unless it has
received the prior written consent of the applicable Purchaser for the specific use contemplated which consent shall not be unreasonably withheld. 
 SECTION 13. NOTICES. 
 All notices, requests, consents and other communications hereunder shall be in writing, shall be sent
by confirmed facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of facsimile or electronic
mail transmission, or when so received in the case of mail or courier, and addressed as follows: 
  

	 	(a)	if to the Company, to: 

 Corcept Therapeutics Incorporated

 149 Commonwealth Drive 
 Menlo Park, California 94025 
 Attention: Chief Executive Officer Facsimile: (650) 327-3218 
 E-Mail: mar2008pipe@corcept.com 
 with a
copy to: 
 Latham & Watkins LLP 
 140 Scott Drive 
 Menlo Park, California 94025 
 Attention: Alan C. Mendelson Facsimile: (650) 463-4693 
 E-Mail: alan.mendelson@lw.com 
 or to such other person at such other place as the Company shall designate
to the Purchasers in writing; and 
  

 15 

 (b) if to the Purchasers, at the address as set forth at the end of this Agreement, or at such other
address or addresses as may have been furnished to the Company in writing. 
 SECTION 14. MISCELLANEOUS. 
 14.1 Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed, waived, discharged, terminated, modified or amended
except upon the written consent of the Company and holders of at least a majority of the Securities. 
 14.2 Purchasers’ Rights under
Alternative Transactions. If the Company receives a proposal (an “Alternative Proposal”) to enter into any agreement or commitment with respect to the purchase of, or the sale or transfer or issuance (whether by merger,
consolidation or otherwise) of, (i) any shares of capital stock of the Company or another entity organized by affiliates of the Company or any securities convertible into or exchangeable for any such stock for the primary purpose of raising
capital, or (ii) all or substantially all of the assets, or any material assets, of the Company or any subsidiary thereof, and the Company’s Board of Directors, in exercising its fiduciary duties under applicable law (including but not
limited to the General Corporation Law of the State of Delaware), determines not to consummate the transactions contemplated by this Agreement, the Company shall endeavor to negotiate with the Purchasers, for a period not to exceed 10 days, a new
transaction with the Purchasers that is comparable to such Alternative Proposal; provided, that in any event, the Purchasers representing a majority of the shares of Common Stock subject to this Agreement shall be entitled to compel the Company to
consummate the transactions contemplated by this Agreement. 
 14.3 Headings. The headings of the various sections of this Agreement
have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. 
 14.4 Severability. In
case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby.

 14.5 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New
York. 
 14.6 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original,
but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. 
 14.7 Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 
 14.8 Entire Agreement. This Agreement and
other documents delivered pursuant hereto, including the exhibit and the Schedule of Exceptions, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. 
  

 16 

 14.9 Payment of Fees and Expenses. 
 (a) On the Closing Date, the Company shall reimburse each Purchaser for all expenses such Purchaser has incurred in connection with this Agreement and the
transactions contemplated hereby, including consulting and reasonable legal fees, up to a maximum aggregate amount equal to $95,000; provided, however, that the Company agrees to reimburse Longitude Capital for all expenses reasonably
incurred in connection with the formation of an escrow account to facilitate the Closing, which expenses shall not be included in the calculation of the maximum aggregate expenses for purposes of this Section 14.9(a). 
 (b) Subject to the provisions of Section 14.9(a) above, each of the Company and the Purchasers shall bear its own expenses and legal fees incurred
on its behalf with respect to this Agreement and the transactions contemplated hereby. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable
attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 [signature
pages follow] 
  

 17 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized representatives as of the day and year first above written. 
  

			
	CORCEPT THERAPEUTICS INCORPORATED
		
	By:	 	 /s/ Joseph K. Belanoff

	Name:	 	Joseph K. Belanoff
	Title:	 	Chief Executive Officer

 SIGNATURE PAGE TO 
 SECURITIES PURCHASE AGREEMENT 

 PURCHASERS: 
  

									
	Longitude Venture Partners, L.P., a Delaware limited partnership	 		 	The 2008 Cook Grantor Retained Annuity Trust
	By: Longitude Capital Partners, LLC	 		 		 	
	Its: General Partner	 		 		 	
					
	By:	 	 /s/ Patrick Enright
	 		 	By:	 	 /s/ Joseph C. Cook, III

	Name:	 	Patrick Enright	 		 	Name:	 	Joseph C. Cook, III
	Title:	 	Managing Member	 		 	Title:	 	Trustee
			
	David L Mahoney & Winnifred C. Ellis 1998 Family Trust	 		 	James N. & Pamela Wilson Trust
					
	By:	 	 /s/ David L. Mahoney
	 		 	By:	 	 /s/ James Wilson

	Name:	 	David L. Mahoney	 		 	Name:	 	James Wilson
	Title:	 	Trustee	 		 	Title:	 	Trustee
			
	Alta BioPharma Partners II, L.P.	 		 	Alta Embarcadero BioPharma Partners II, LLC
					
	By:	 	 /s/ Alix Marduel
	 		 	By:	 	 /s/ Alix Marduel

	Name:	 	Alix Marduel	 		 	Name:	 	Alix Marduel
	Title:	 	Managing Director	 		 	Title:	 	Manager
			
	Sutter Hill Ventures, a California Limited Partnership	 		 	G. Leonard Baker, Jr. and Mary Anne Baker, Co-Trustees of the Baker Revocable Trust U/A/D 2/3/03
					
	By:	 	 /s/ G. Leonard Baker, Jr.
	 		 	By:	 	 /s/ G. Leonard Baker, Jr.

	Name:	 	G. Leonard Baker, Jr.	 		 	Name:	 	G. Leonard Baker, Jr.
	Title:	 	Managing Director of the General Partner	 		 	Title:	 	Trustee
			
	Saunders Holdings, L.P.	 		 	Tench Coxe and Simone Otus Coxe, Co-Trustees of the Coxe Revocable Trust U/A/D 4/23/98
					
	By:	 	 /s/ G. Leonard Baker, Jr.
	 		 	By:	 	 /s/ Tench Coxe*

	Name:	 	G. Leonard Baker, Jr.	 		 	Name:	 	Tench Coxe
	Title:	 	General Partner	 		 	Title:	 	Trustee
			
	Gregory P. Sands and Sarah J.D. Sands as Trustees of Gregory P. and Sarah J.D. Sands Trust Agreement dated 2/24/99	 		 	Tallack Partners, L.P.
					
	By:	 	 /s/ Gregory P. Sands*
	 		 	By:	 	 /s/ James C. Gaither*

	Name:	 	Gregory P. Sands	 		 	Name:	 	James C. Gaither
	Title:	 	Trustee	 		 	Title:	 	General Partner
			
	James N. White and Patricia A. O’Brien as Trustees of the White Family Trust U/A/D 4/3/97	 		 	Jeffrey W. Bird and Christina R. Bird as Trustees of Jeffrey W. and Christina R. Bird Trust Agreement dated 10/31/00
					
	By:	 	 /s/ James N. White*
	 		 	By:	 	 /s/ Jeffrey W. Bird*

	Name:	 	James N. White	 		 	Name:	 	Jeffrey W. Bird
	Title:	 	Trustee	 		 	Title:	 	Trustee

  

 1 

									
	Ronald Daniel Bernal and Pamela Mayer Bernal as Trustees of Bernal Family Trust U/D/T 11/3/95	 		 	Michael I. Naar and Diane J. Naar as Trustees of Naar Family Trust U/A/D 12/22/94
					
	By:	 	 /s/ Ronald D. Bernal*
	 		 	By:	 	 /s/ Diane J. Naar*

	Name:	 	Ronald D. Bernal	 		 	Name:	 	Diane J. Naar
	Title:	 	Trustee	 		 	Title:	 	Trustee
			
	Robert Yin and Lily Yin as Trustees of Yin Family Trust dated March 1, 1997	 		 	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Rollover)
					
	By:	 	 /s/ Robert Yin
	 		 	By:	 	 /s/ Vicki M. Bandel

	Name:	 	Robert Yin	 		 	Name:	 	Vicki M. Bandel
	Title:	 	Trustee	 		 	Title:	 	Assistant Vice President & Trust Officer
			
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw (Rollover)	 		 	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet (Rollover)
					
	By:	 	 /s/ Vicki M. Bandel
	 		 	By:	 	 /s/ Vicki M. Bandel

	Name:	 	Vicki M. Bandel	 		 	Name:	 	Vicki M. Bandel
	Title:	 	Assistant Vice President & Trust Officer	 		 	Title:	 	Assistant Vice President & Trust Officer
			
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO William H Younger, Jr.	 		 	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Sherryl W. Casella
					
	By:	 	 /s/ Vicki M. Bandel
	 		 	By:	 	 /s/ Vicki M. Bandel

	Name:	 	Vicki M. Bandel	 		 	Name:	 	Vicki M. Bandel
	Title:	 	Assistant Vice President & Trust Officer	 		 	Title:	 	Assistant Vice President & Trust Officer
			
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David L. Anderson	 		 	Paperboy Ventures, LLC
					
	By:	 	 /s/ Vicki M. Bandel
	 		 	By:	 	 /s/ Anthony C. Garland

	Name:	 	Vicki M. Bandel	 		 	Name:	 	Anthony C. Garland
	Title:	 	Assistant Vice President & Trust Officer	 		 	Title:	 	CFO & Managing Director
			
	VP Company Investments 2008, LLC	 		 	Alan C. and Agnes B. Mendelson Family Trust
					
	By:	 	 /s/ Alan C. Mendelson
	 		 	By:	 	 /s/ Alan C. Mendelson

	Name:	 	Alan C. Mendelson	 		 	Name:	 	Alan C. Mendelson
	Title:	 	Member of Management Committee	 		 	Title:	 	Trustee
			
	Vaughn Bryson	 		 	Roy M. Barbee
					
	By:	 	 /s/ Vaughn D. Bryson
	 		 	By:	 	 /s/ Roy M. Barbee

	Name:	 	Vaughn D. Bryson	 		 	Name:	 	Roy M. Barbee
			
	Douglas G & Irene E. DeVivo Rev. Trust	 		 	Black Point Group LP
					
	By:	 	 /s/ Douglas G. DeVivo
	 		 	By:	 	 /s/ Benjamin Shaw

	Name:	 	Douglas G. DeVivo	 		 	Name:	 	Benjamin Shaw
	Title:	 	Trustee	 		 	Title:	 	Partner
				
	Bruce Hardy McLain	 		 		 	
					
	By:	 	 /s/ Bruce Hardy McLain
	 		 		 	
	Name:	 	Bruce Hardy McLain	 		 		 	
	Title:	 	Managing Partner	 		 		 	

  

	*	signed by Robert Yin Under Power of Attorney 

  

 2 

 EXHIBIT A 
 SCHEDULE OF PURCHASERS 
  

											
	 Name and Address
	  	Number of
Shares	  	Aggregate
Purchase
Price of
Shares	  	Number of
Warrants	  	Aggregate
Purchase
Price of
Warrants
	Longitude Venture Partners, L.P.	  	3,530,450	  	$	9,779,347	  	1,765,225	  	$	220,653
	The 2008 Cook Grantor Retained Annuity Trust	  	176,522	  	$	488,967	  	88,261	  	$	11,033
	David L Mahoney & Winnifred C. Ellis 1998 Family Trust	  	70,609	  	$	195,587	  	35,304	  	$	4,413
	James N. & Pamela Wilson Trust	  	35,304	  	$	97,793	  	17,652	  	$	2,207
	Alta BioPharma Partners II, L.P.	  	1,045,921	  	$	2,897,201.34	  	522,960	  	$	65,370.00
	Alta Embarcadero BioPharma Partners II, LLC	  	13,214	  	$	36,602.78	  	6,607	  	$	825.88
	Sutter Hill Ventures, a California Limited Partnership	  	693,118	  	$	1,919,936.86	  	346,559	  	$	43,319.88
	G. Leonard Baker, Jr. and Mary Anne Baker, Co-Trustees of the Baker Revocable Trust U/A/D 2/3/03	  	335,393	  	$	929,038.61	  	167,696	  	$	20,962.00
	Saunders Holdings, L.P.	  	105,914	  	$	293,381.78	  	52,957	  	$	6,619.63
	Tench Coxe and Simone Otus Coxe, Co-Trustees of the Coxe Revocable Trust U/A/D 4/23/98*	  	147,743	  	$	409,248.11	  	73,871	  	$	9,233.88
	Gregory P. Sands and Sarah J.D. Sands as Trustees of Gregory P. and Sarah J.D. Sands Trust Agreement dated 2/24/99	  	17,940	  	$	49,693.80	  	8,970	  	$	1,121.25
	Tallack Partners, L.P.	  	17,574	  	$	48,679.98	  	8,787	  	$	1,098.38
	James N. White and Patricia A. O’Brien as Trustees of the White Family Trust U/A/D 4/3/97	  	17,233	  	$	47,735.41	  	8,616	  	$	1,077.00
	Jeffrey W. Bird and Christina R. Bird as Trustees of Jeffrey W. and Christina R. Bird Trust Agreement dated 10/31/00	  	15,518	  	$	42,984.86	  	7,759	  	$	969.88
	Ronald Daniel Bernal and Pamela Mayer Bernal as Trustees of Bernal Family Trust U/D/T 11/3/95	  	2,684	  	$	7,434.68	  	1,342	  	$	167.75
	Michael I. Naar and Diane J. Naar as Trustees of Naar Family Trust U/A/D 12/22/94	  	114	  	$	315.78	  	57	  	$	7.13
	Robert Yin and Lily Yin as Trustees of Yin Family Trust dated March 1, 1997	  	271	  	$	750.67	  	135	  	$	16.88
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Rollover)	  	579	  	$	1,603.83	  	289	  	$	36.13

  

 3 

											
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw (Rollover)	  	806	  	$	2,232.62	  	403	  	$	50.38
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet (Rollover)	  	6,151	  	$	17,038.27	  	3,075	  	$	384.38
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO William H Younger, Jr.	  	115,691	  	$	320,464.07	  	57,845	  	$	7,230.63
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Sherryl W. Casella	  	2,938	  	$	8,138.26	  	1,469	  	$	183.63
	Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David L. Anderson	  	109,036	  	$	302,029.72	  	54,518	  	$	6,814.75
	Paperboy Ventures, LLC	  	2,118,270	  	$	5,867,608	  	1,059,135	  	$	132,392
	VP Company Investments 2008, LLC	  	8,826	  	$	24,448.37	  	4,413	  	$	552
	Alan C. and Agnes B. Mendelson Family Trust	  	8,826	  	$	24,448.37	  	4,413	  	$	552
	Vaughn Bryson	  	70,609	  	$	195,587	  	35,304	  	$	4,413
	Roy M. Barbee	  	105,913	  	$	293,380	  	52,956	  	$	6,620
	Douglas G & Irene E. DeVivo Rev. Trust	  	35,304	  	$	97,793	  	17,652	  	$	2,207
	Black Point Group LP	  	88,261	  	$	244,484	  	44,130	  	$	5,516
	Bruce Hardy McLain	  	26,478	  	$	73,345	  	13,239	  	$	1,655

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]